Logo     Print Page  Close Window


SEC Filings


8-K
FIBROCELL SCIENCE, INC. filed this Form 8-K on 05/10/2018
Entire Document
 
Document


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________________________________________________________________________________________

FORM 8-K
______________________________________________________________________________________________________

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 10, 2018
______________________________________________________________________________________________________
http://api.tenkwizard.com/cgi/image?quest=1&rid=23&ipage=12243427&doc=30
FIBROCELL SCIENCE, INC.
(Exact Name of Registrant as Specified in its Charter)
______________________________________________________________________________________________________
DELAWARE
001-31564
87-0458888
(State or Other Jurisdiction of Incorporation or Organization)
(Commission File No.)
(I.R.S. Employer Identification No.)

405 EAGLEVIEW BLVD., EXTON, PA 19341
(Address of principal executive offices and zip code)

(484) 713-6000
(Registrant’s telephone number, including area code)
(Former name or former address, if changed from last report)
______________________________________________________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
q
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
q
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
q
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
q
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   o     







Item 2.02 Results of Operations and Financial Condition.
On May 10, 2018, Fibrocell Science, Inc. issued a press release announcing financial results for the three months ended March 31, 2018 and recent operational highlights. A copy of this press release is furnished herewith as Exhibit 99.1 and incorporated by reference herein.

Item 8.01 Other Events.    
On May 10, 2018, Fibrocell Science, Inc. posted an updated Corporate Presentation on its website www.fibrocell.com. A copy of the presentation is filed herewith as Exhibit 99.2 and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d)    Exhibits










SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
 
 
 
Fibrocell Science, Inc.
By:
 
/s/ John M. Maslowski
 
 
John M. Maslowski
 
 
President and Chief Executive Officer
Date: May 10, 2018



a050818finalfcsc1q18earn
Fibrocell Reports First Quarter 2018 Financial Results and Recent Highlights - Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT - EXTON, PA – May 10, 2018 – Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today reported financial results for the first quarter ended March 31, 2018 and recent operational highlights. Fibrocell will host a conference call and webcast today at 8:30 a.m. EDT. “Our achievements in the first quarter of 2018 have set the stage for continued progress of Fibrocell’s gene therapy clinical programs that address rare conditions of the skin and connective tissue with high unmet needs,” said John Maslowski, President and Chief Executive Officer of Fibrocell. “In January, we obtained allowance from the U.S. Food and Drug Administration to enroll pediatric patients in the Phase 2 portion of our Phase 1/2 clinical trial of FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa. In addition, the Phase 1 portion of this trial continued to advance and we expect to report additional interim adult data in the second quarter of 2018.” “Furthermore, our FCX-013 program for the treatment of moderate to severe localized scleroderma made important progress. In March 2018, Fibrocell was granted allowance by the FDA of the Investigational New Drug Application for FCX-013 to proceed to clinical trials,” said Mr. Maslowski. Recent program highlights and new updates are as follows: FCX-007  Fibrocell obtained allowance from the U.S. Food and Drug Administration (FDA) to initiate enrollment of pediatric patients in the Phase 2 portion of its Phase 1/2 clinical trial of FCX- 007, based on evidence of safety and potential benefit of FCX-007 in adult patients dosed in the Phase 1 portion of the clinical trial. Fibrocell plans to enroll six patients ages seven and older in the Phase 2 portion of the clinical trial. One recessive dystrophic epidermolysis bullosa (RDEB) adult patient has been enrolled in Phase 2, and dosing is expected to occur in the second quarter of 2018.  Fibrocell expects to report additional interim data on the adult patients in the Phase 1 portion of its Phase 1/2 clinical trial of FCX-007 and provide a trial update in the second quarter of 2018, which includes an oral presentation at the 7th International Investigative Dermatology meeting on May 19, 2018.  Fibrocell expects to complete enrollment of patients in the Phase 2 portion of the Phase 1/2 clinical trial of FCX-007 in the third quarter of 2018. Another interim data report and trial update is expected in the first quarter of 2019.


 
FCX-013  Fibrocell obtained FDA allowance of the Investigational New Drug Application for FCX-013 to progress to clinical trials for the treatment of moderate to severe localized scleroderma. Fibrocell expects to initiate enrollment for a Phase 1/2 clinical trial of FCX-013 in the third quarter of 2018. Corporate  On April 18, 2018, Fibrocell announced that its Board of Directors is conducting a comprehensive review of strategic alternatives focused on maximizing stockholder value. Fibrocell has engaged Canaccord Genuity LLC as its strategic financial advisor to assist with this review process. The Board of Directors has established a Special Committee to explore and evaluate potential strategic alternatives which may include a sale of the Company, a business combination, a merger or reverse merger with another company, a strategic investment into the Company, a sale, license or other disposition of corporate assets of the Company or continuing with the current business plan. Fibrocell has not set a timetable for completion of the review process. No decision has been made as to whether the Company will engage in a transaction or transactions, and there can be no assurance that this process will result in any transaction, or the terms or timing of any potential transaction. Financial Results for the Three Months Ended March 31, 2018 For the three months ended March 31, 2018, Fibrocell reported a diluted net loss of $0.11 per share, compared to a diluted net loss of $0.60 per share for the same period in 2017. The 2018 period included approximately $0.2 million of non-cash warrant revaluation income, as compared to approximately $0.1 million of non-cash warrant revaluation expense for the same period in 2017. Additionally, the 2018 period included non-cash deemed dividends on Series A preferred stock of approximately $0.1 million as compared to the approximately $3.7 million in non-cash deemed dividends included in the 2017 period, increasing the net loss attributable to common stockholders. Research and development expenses decreased 54.9% to approximately $1.3 million for the three months ended March 31, 2018, as compared to approximately $3.0 million for the same three-month period in 2017. This decrease was due primarily to decreased costs for our FCX-007 program of approximately $1.3 million, or 105.4%, for the three months ended March 31, 2018 compared to the same period in 2017. These decreased costs were primarily the result of transitioning from dosing of adult patients and analysis of data in the Phase 1 portion of the Phase 1/2 clinical trial to recruitment for the Phase 2 portion of the trial, and moving our manufacturing operations in-house from a third party contractor. Costs for our FCX-013 program decreased approximately $0.4 million, or 59.9%, for the three months ended March 31, 2018 compared to the same period in 2017. This decrease was related primarily to decreased costs from our clinical partner Intrexon Corporation of approximately $0.4 million, as substantially all of the costs of the pre-clinical phase of the project were incurred at the end of 2017. Selling, general and administrative expenses increased 10.7% to approximately $1.6 million for the three months ended March 31, 2018, as compared to approximately $1.5 million for the same


 
three-month period in 2017. This increase was due primarily to the credits for stock compensation expense recorded in the 2017 period, due to the forfeiture of stock options by prior management that left the Company in the fourth quarter of 2016 and the first quarter of 2017. As of March 31, 2018, the Company had cash and cash equivalents of approximately $12.2 million and working capital of approximately $10.8 million. Fibrocell used approximately $4.8 million in cash for operations during both of the three month periods ended March 31, 2018 and 2017. The Company believes that its cash and cash equivalents will be sufficient to fund operations into the first quarter of 2019. Conference Call and Webcast To participate on the live call, please dial 866-548-4713 (domestic) or +1-323-794-2093 (international), and provide the conference code 3897293 five to ten minutes before the start of the call. The conference call will also be webcast live under the investor relations section of Fibrocell's website at www.fibrocell.com/investors/events and will be archived there for 30 days following the call. About Fibrocell Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Fibrocell’s most advanced product candidate, FCX-007, is the subject of a Phase 1/2 clinical trial for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also developing FCX-013, the Company’s product candidate for the treatment of moderate to severe localized scleroderma. Fibrocell’s gene therapy portfolio is being developed in collaboration with Intrexon Corporation (NYSE: XON), a leader in synthetic biology. For more information, visit www.fibrocell.com or follow Fibrocell on Twitter at @Fibrocell. Trademarks Fibrocell, the Fibrocell logo, and Fibrocell Science are trademarks of Fibrocell Science, Inc. and/or its affiliates. All other names may be trademarks of their respective owners. Forward-Looking Statements This press release contains, and our officers and representatives may from time to time make, statements that are “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this purpose and include, among others, statements relating to: Fibrocell’s expectations regarding the exploration of strategic alternatives; the timing of dosing and reporting of interim data and trial updates for its Phase 1/2 clinical trial of FCX-007; the completion of enrollment in the Phase 2 portion of its Phase 1/2 clinical trial of FCX-007; the initiation of the Phase 1 portion of its Phase 1/2 clinical trial for FCX- 013; the potential for FCX-007 and FCX-013 to receive Priority Review Vouchers upon market authorization; the potential advantages of Fibrocell’s product candidates; the sufficiency of the


 
Company’s cash and cash equivalents to fund operations into the first quarter of 2019 and other statements regarding Fibrocell’s future operations, financial performance and financial position, prospects, strategies, objectives and other future events. Forward-looking statements are based upon management’s current expectations and assumptions and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated herein including, among others: uncertainties associated with being able to identify, evaluate and complete any strategic transaction or alternative; the impact of the announcement of the Board of Directors’ review of strategic alternatives, as well as any strategic transaction or alternative that may be pursued, on the Company's business, including its financial and operating results and its employees; that interim clinical trial results are not necessarily indicative of final clinical results and final clinical trial results may not be positive with regard to safety or efficacy of FCX-007 or FCX-013; uncertainties and delays relating to the initiation, enrollment and completion of pre- clinical studies and clinical trials; whether pre-clinical study and clinical trial results will validate and support the safety and efficacy of Fibrocell’s product candidates; unanticipated or excess costs relating to the development of Fibrocell’s gene therapy product candidates; Fibrocell’s ability to obtain additional capital to continue to fund operations; Fibrocell’s ability to maintain its collaboration with Intrexon Corporation; and the risks, uncertainties and other factors discussed under the caption “Item 1A. Risk Factors” in Fibrocell’s most recent Form 10-K filing and Form 10-Q filings. As a result, you are cautioned not to place undue reliance on any forward-looking statements. While Fibrocell may update certain forward-looking statements from time to time, Fibrocell specifically disclaims any obligation to do so, whether as a result of new information, future developments or otherwise. # # # Investor & Media Relations Contact: Karen Casey 484.713.6133 kcasey@fibrocell.com


 
Fibrocell Science, Inc. Condensed Consolidated Statements of Operations (unaudited) ($ in thousands, except share and per share data) Three Months Ended March 31, 2018 2017 Total revenues $ — $ — Total cost of revenue — — Gross profit (loss) — — Research and development expense 1,645 1,464 Research and development expense - related party (see Note 8) (303 ) 1,509 Selling, general and administrative expense 1,639 1,481 Operating loss (2,981 ) (4,454 ) Other income (expense): Warrant revaluation income (expense) 235 (46 ) Derivative revaluation expense (63 ) (312 ) Interest expense (190 ) (183 ) Other income (expense), net 98 (12 ) Loss before income taxes (2,901 ) (5,007 ) Income taxes — — Net loss (2,901 ) (5,007 ) Dividend paid in-kind to preferred stockholders (82 ) (20 ) Deemed dividend on preferred stock (see Note 10) (121 ) (3,734 ) Net loss attributable to common stockholders $ (3,104 ) $ (8,761 ) Per Share Information: Net loss: Basic $ (0.11 ) $ (0.60 ) Diluted $ (0.11 ) $ (0.60 ) Weighted average number of common shares outstanding: Basic 28,356,351 14,694,613 Diluted 28,356,351 14,697,210 Condensed Consolidated Balance Sheets Data: March 31, December 31, 2018 2017 Cash and cash equivalents $ 12,201 $ 17,417 Working capital 10,811 13,477 Total assets 14,145 19,411 Warrant liability, long term 838 1,073 Total liabilities 7,886 10,404 Total stockholders’ equity 6,259 9,007


 
afinalfibrocellcorpora
Corporate Presentation May 10, 2018


 
Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward- looking statements for this purpose and include, among others, statements relating to: the potential advantages of our product candidates; the initiation, design and timing of pre-clinical studies and clinical trials and activities and the reporting of the results thereof; the timing of regulatory submissions and actions; expected milestones; and all other statements relating to our future operations, future financial performance, future financial condition, prospects or other future events. Forward-looking statements are based upon our current expectations and assumptions and are subject to a number of known and unknown risks, uncertainties and other factors that could cause actual results to differ materially and adversely from those expressed or implied by such statements. Factors that could cause or contribute to such differences include, among others: that interim clinical trial results are not necessarily indicative of final clinical results and final clinical trial results may not be positive with regard to safety or efficacy of FCX-007 or FCX-013; uncertainties and delays relating to the initiation, enrollment and completion of pre-clinical studies and clinical trials, including with respect to FCX-007, FCX-013 and our other product candidates; whether pre-clinical study and clinical trial results will validate and support the safety and efficacy of our product candidates; the risk that results seen in pre-clinical studies may not be replicated in humans; varying interpretation of pre-clinical and clinical data; unanticipated or excess costs relating to the development of our gene therapy product candidates; our ability to obtain additional capital to continue to fund operations; our ability to maintain our collaboration with Intrexon Corporation; the results of our Board of Directors’ consideration of strategic alternatives; and the other factors discussed under the caption “Item 1A. Risk Factors” in our most recent Form 10-K and Form 10-Qs which are available through the “Investors—SEC Filings” page of our website at www.fibrocell.com. As a result, you should not place undue reliance on forward-looking statements. The forward-looking statements made in connection with this presentation represent our views only as of the date of this presentation (or any earlier date indicated in such statement). While we may update certain forward-looking statements from time to time, we specifically disclaim any obligation to do so, even if new information becomes available in the future. 2


 
Investment Highlights • Medical breakthroughs for rare diseases of the skin and connective tissue Focus on Rare Skin • Unmet needs with no approved therapies Diseases • Significant mortality and morbidity impact on pediatric populations Proprietary Ex-Vivo Gene • Autologous fibroblasts derived from skin are the vehicle to deliver target proteins Modified Fibroblast locally to the site of disease Platform • Extensive experience culturing dermal fibroblasts, including commercial scale • FCX-007 for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) . Obtained FDA allowance to initiate enrollment of pediatric patients in Phase 2 . Two Clinical Trial Programs Well tolerated safety and positive early trends noted in pharmacology and wound healing • FCX-013 for the treatment of moderate to severe Localized Scleroderma . IND allowed by FDA, expect enrollment to begin 3Q2018 • Regulatory advantages including more frequent communications with FDA, eligibility Multiple FDA Designations for Accelerated Approval and Priority Review, and Rolling Review • Two Rare Pediatric Disease Designations to potentially receive Priority Review Vouchers (PRVs) upon market authorization • In-house 13,000 square foot cGMP cell therapy manufacturing facility supporting both Internal Manufacturing FCX-007 and FCX-013 Infrastructure • Existing capacity to serve the U.S. RDEB market 3


 
Development Pipeline Phase 1/2 Program Condition Target Research Pre-Clinical Clinical Trials FDA Designations Orphan Drug Type VII FCX-007 Recessive Dystrophic Rare Pediatric Disease Epidermolysis Bullosa Collagen (RDEB) Fast Track FCX-013 Moderate to Severe Orphan Drug MMP-1 Localized Scleroderma Rare Pediatric Disease Research Arthritis and Related TBD Conditions Portfolio being developed in collaboration with 4


 
Our Proprietary Fibroblast Platform Viral Vector Delivery Vehicle Vector Autologous fibroblasts Lentiviral vector gene transfer • Readily sourced, as fibroblasts • 3rd generation and self- are the most common cell type in skin and connective tissue inactivating • • Reduced rejection and Accommodates large gene immunogenicity concerns constructs • • Established manufacturing Transduces both dividing and non- process and regulatory dividing cells pathway Ex-vivo Gene • Target gene integration for long- term expression of the protein Ex-VivoModifiedGene Modified Cells Cells FCX-007 autologous dermal fibroblasts in culture 5


 
Personalized Biologics Approach 6


 
FCX-007 – Recessive Dystrophic Epidermolysis Bullosa FCX-007 is a dermal fibroblast transduced with a lentiviral vector encoded with the gene for type VII collagen Orphan Drug Designation Rare Pediatric Disease Designation Fast Track Designation 7


 
About RDEB Recessive Dystrophic Epidermolysis Bullosa (RDEB) is a monogenic disease resulting in chronic skin blistering and wounding Disease Current Treatments Epidemiology • Cause: A mutation in the • Current treatments only Dystrophic EB (DEB) COL7A1 gene that address symptoms ~5,500 – 12,500 US3 encodes for COL7 . Bandaging & • RDEB • Devastating, progressive, antibiotics – ~1,100 – 2,500 US4 painful blistering disease bandaging alone can that often leads to death exceed $10,000 per • Diagnosed at infancy month2 • High mortality rate – 76% . Feeding tubes of RDEB patients do not . Surgery, including 1 live beyond their 30’s hand and esophageal Photo credit: Science Photo Library 8


 
FCX-007 Phase 1/2 Clinical Trial Design A Phase 1/2 Trial of FCX-007 (Genetically-Modified Autologous Human Dermal Title Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa (RDEB) NCT02810951 Primary Objective To evaluate the safety of a single intradermal injection session of FCX-007 Secondary Objective To evaluate wound healing and pharmacology of FCX-007 Investigator Sites Stanford University School of Medicine and Children’s Hospital Colorado Phase 1 Status • Four patients enrolled and dosed, continuing follow-up visits through 25 weeks • Next interim data readout expected in 2Q2018 • Obtained FDA allowance to initiate enrollment of pediatric patients Phase 2 Status • Six patients ages seven and older targeted for enrollment • One adult patient enrolled; expect completion of enrollment 3Q2018 9


 
FCX-007 Interim Data Readout • Interim readout of data for three NC1+ adult Phase 1 patients, 12 weeks post- administration • Single injection session of FCX-007 to target wounds or preliminary safety assessment • Five wounds treated over three patients ranging from 4.4cm2 to 13.1cm2 in size • FCX-007 was well tolerated through 12 weeks post-administration . No serious adverse events or product related adverse events . No replication competent lentivirus (RCL) detected . Low to no autoantibody response detected • Positive early trends noted in pharmacology signals and wound healing • The Data Safety Monitoring Board (DSMB) concluded that safety and potential benefit were established, and allowed continuation of enrollment and dosing 10


 
FCX-007 Interim Readout: Wound Healing • Digital images captured and tracings performed Post- Treated or Percent Healing Number of . Skin tattoos and transparent overlays used as landmarks Baseline Untreated Wounds Meeting Visit Wounds Criteria • Wounds monitored in the study prior to dosing were open 4 weeks Treated > 75% healed 100% (5/5) at each monitoring visit up to 8 months Untreated < 25% healed 80% (4/5) • A matched size untreated wound for each treated wound on the same patient was also monitored and evaluated 12 weeks Treated > 70% healed 80% (4/5)* • Compared to the baseline measurement collected at Day 0 Untreated < 25% healed 80% (4/5) pre-administration, wounds healing after a single injection session of FCX-007 resulted as follows: * Increase in size for one wound from the data set may have potentially destabilized due to biopsy samples collected in the center of the wound bed Day 0 Pre-Administration 4 Weeks 12 Weeks Treated area: 10.3cm2 Right posterior leg • White arrows denote tracking tattoo • Dash lines represent target treatment area • Day 0 pen markings denote injection locations • 4 week solid lines denote remaining wounded areas 75% healed 100% healed 11


 
FCX-007 Interim Readout: Pharmacology • Variable pharmacology signals detected throughout the data set in each patient for one or more assays through 12 weeks post-administration (qPCR, electron microscopy, immunofluorescence) . Anchoring fibrils have not been detected to date, whereas COL7 mRNA and COL7 protein have been confirmed in multiple patient samples, including one that detected linear expression of COL7 • Linear expression of COL7 in the basement membrane zone (BMZ) and expression in the dermis detected through 12 weeks post-administration Texas Red – C7/fNC1 Texas Red – C7/fNC1 + DAPI + FITC – laminin 332 12


 
FCX-013 – Moderate to Severe Localized Scleroderma FCX-007 is a dermal fibroblast transduced with a lentiviral vector encoded with the gene for MMP-1, under control of the RheoSwitch Therapeutic System® (RTS®) Orphan Drug Designation Rare Pediatric Disease Designation 13


 
About Localized Scleroderma Disease Epidemiology • Excess production of collagen • Localized Scleroderma characterized by skin fibrosis ~160,000 sufferers US5 comprised of different sub- • Focus on moderate to severe types subtypes . ~90,000 patients are • Thickening may extend to considered moderate to 6 underlying tissue and muscle severe in children which may impair growth in affected limbs or forehead Current Treatments Current treatments: • Lesions appearing across joints impair motion and may • Systemic or topical be permanent corticosteroids target inflammation • UVA light therapy • Physical therapy Photo: Reprinted from the Journal of the American Academy of Dermatology, Volume 59, Issue 3, Stéphanie Christen-Zaech, Miriam D. Hakim, F. Sule Afsar, Amy S. Paller. Pediatric morphea (localized scleroderma): Review of 136 patients, Figure 1, pp. 385-396. Copyright Sept 2008. Used with permission from Elsevier Ltd. 14


 
FCX-013 Moving into Clinical Trials • Product profile . Dermal fibroblasts genetically modified using lentivirus and encoded for matrix metalloproteinase 1 (MMP-1), a protein responsible for breaking down collagen . Incorporates Intrexon’s RheoSwitch Therapeutic System® (RTS®) to control protein expression • Activated by an oral ligand (veledimex) • FDA allowed IND • Completed GLP toxicology/biodistribution study . Bleomycin fibrosis model using immunocompromised mice (NOD/SCID) . No test article-related clinical observations, body weight changes, changes in clinical pathology parameters, gross observations or organ weight change . No significant vector biodistribution to target organs • Expect to initiate enrollment for a Phase 1/2 clinical study in 3Q2018 15


 
FCX-013 Phase 1/2 Clinical Trial Design A Phase 1/2 Study of a Combination of FCX-013 (Genetically-Modified Human Title Dermal Fibroblasts) plus Veledimex for the Treatment of Moderate to Severe Scleroderma (Morphea) Primary Objective To evaluate the safety of a single intradermal injection session of FCX-013 To evaluate fibrosis resolution through the following measurements: Secondary Objectives • Histology • MRI, ultrasound and durometry • Various scale assessments • 10 (approximately 5 per Phase) Number of Patients • Staggered enrollment for first 3 adults • Starting with adult patients; addition of pediatric patients after submission and approval of safety and activity data from adult patients to FDA and the DSMB Status Initiate enrollment of Phase 1 adult patients in 3Q2018 16


 
FCX-013 Proof-of-Concept Study • Study Design D0 D28 D29 D39 . Bleomycin treated SCID mouse model . N=30 mice over test and control groups Blecomycin treatments Ligand Treatment . Assessed histologically for reduction of dermal thickness and sub-dermal muscle in the presence Cell Harvest skin of FCX-013 and oral ligand injection samples • Result . Bleomycin treatment resulted in skin fibrosis, measured by a significant increase in dermal thickness . Demonstrated that FCX-013 with ligand reduced the dermal thickness of fibrotic tissue to levels similar to non-bleomycin (saline) with ligand treated skin . Further reduced the thickness of the sub-dermal muscle layer CONTROL: Saline (no Bleo) No Cells CONTROL: Bleomycin Non-Modified Cells TEST: Bleomycin FCX-013 17


 
Manufacturing Experience and Solutions Fibrocell’s existing cGMP cell therapy manufacturing facility in Exton, PA has been designated as the production site for FCX-007 and FCX-013 • ~13,000 square foot facility includes: . Cleanroom for cell culture manufacturing . On-site quality control testing laboratories . Cryogenic storage . Warehouse and distribution areas . Centrally monitored • Previous experience with commercial cell therapy manufacturing • Site for remaining clinical and future commercial manufacture of FCX-007 and FCX-013 • Existing capacity to serve the U.S. RDEB market commercially • In-house manufacturing expertise for fibroblast-based autologous cell and gene therapy products • Multiple site inspections by FDA 18


 
FCX-007 Anticipated Milestones 2018-2019 January 2018 2Q2018 3Q2018 1Q2019 FDA allowance of Interim Phase 1 data Complete enrollment Interim data readout pediatric patient readout and trial of Phase 2 patients and trial update FCX-007 enrollment in Phase 2 update Dose first Phase 2 patient FCX-013 March 2018 3Q2018 FDA allowance of IND Initiate enrollment of Phase 1 patients Category Amount Cash at March 31, 2018 $12.2M Share Count (Outstanding/Fully Diluted) 28.3M/63.7M as of March 31, 2018 Cash Runway Cash into 1Q2019 19


 
Investment Highlights • Medical breakthroughs for rare diseases of the skin and connective tissue Focus on Rare Skin • Unmet needs with no approved therapies Diseases • Significant mortality and morbidity impact on pediatric populations Proprietary Ex-Vivo Gene • Autologous fibroblasts derived from skin are the vehicle to deliver target proteins Modified Fibroblast locally to the site of disease Platform • Extensive experience culturing dermal fibroblasts, including commercial scale • FCX-007 for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) . Obtained FDA allowance to initiate enrollment of pediatric patients in Phase 2 . Two Clinical Trial Programs Well tolerated safety and positive early trends noted in pharmacology and wound healing • FCX-013 for the treatment of moderate to severe Localized Scleroderma . IND allowed by FDA, expect enrollment to begin 3Q2018 • Regulatory advantages including more frequent communications with FDA, eligibility Multiple FDA Designations for Accelerated Approval and Priority Review, and Rolling Review • Two Rare Pediatric Disease Designations to potentially receive Priority Review Vouchers (PRVs) upon market authorization • In-house 13,000 square foot cGMP cell therapy manufacturing facility supporting both Internal Manufacturing FCX-007 and FCX-013 Infrastructure • Existing capacity to serve the U.S. RDEB market 20


 
References 1 Fine, J. et. al. (ed.). Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances and the Findings of the National Epidermolysis Bullosa Registry. The John Hopkins University Press, Baltimore, MD, 1999. 2 The Dystrophic Epidermolysis Research Association of America (DebRA). EB brochure, page 6: http://www.debra.org/DebraBrochure; accessed 11/10/17. 3 DEBRA International. What is EB Infographic: http://www.debra-international.org/what-is-eb.html; accessed 11/10/17. 4 Murauer, E, Koller, U, Pellegrini, G, De Luca, M, Bauer, J. Advances in Gene/Cell Therapy in Epidermolysis Bullosa. The Keio Journal of Medicine. 2015; 64. 5 Peterson LS et al. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960-1993. J Rheumatol. 1997; 24:73-80. 6Leitenberger, et. al. Distinct autoimmune syndromes in morphea: a case study of 245 adult and pediatric cases. Arch Dermatol. 2009 May; 145(5):545-550. 21